3 results
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Primary objective: to asses the quality of a reservoir which removes leukocytes and lipids combined with the Continuous Autotransfusion System (CATS) regarding the autotransfusion product in general and red blood cell function in particular.…
There are two treatment groups in this study: one with participants at low risk of deterioration and one with participants at standard risk of deterioration. The primary objective for each group is described below.-Low Risk group: To describe the…